Chelsie Derman

A new study provides insight into the effectiveness of IFX-dyyb in a real-world US population of RA patients, showing how the biosimilar compares to other treatments.

A new study found a single low dose of esketamine given shortly after childbirth reduced major depressive episodes at 42 days postpartum by about 3 quarters.

Patients on psilocybin for depression or anxiety reported tolerable adverse events, including headache, nausea, anxiety, dizziness, and elevated blood pressure.

A new study found patients with a BMI of 32 to 35 have lower odds of responding to the hypoglossal nerve stimulation for OSA compared to patients with a lower BMI.

Sibling control analyses showed acetaminophen use during pregnancy was not associated with an offspring’s risk of autism, ADHD, or intellectual disability.

A study using machine learning models found “I” usage on Facebook posts does not predict depression severity in Black individuals.

EMERGENT-3 trial showed xanomeline-trospium was effective in improving schizophrenia symptoms at 52 weeks, for participants who took either placebo or KarXT in acute trials.

The study highlights how the experience of loneliness for care partners of people with dementia changes relationship roles throughout the dementia trajectory.

A new study showed how taking alcohol use disorder medication following an alcohol-related hospitalization discharge was linked to a reduction in return to hospital in 30 days.

A trial demonstrated the reliability and validity of a smartphone app’s capability of detecting frontotemporal lobar degeneration.

Lykos Therapeutics announced the FDA accepted its NDA for MDMA-assisted therapy for individuals with PTSD on February 9, 2024, backed by phase 3 data showing the drug’s efficacy.

This sleep month in review highlights the 6 top sleep pieces in March, from FDA news, topline data, and pieces exploring how daylight savings and long COVID impact sleep.

Although still recruiting, the first patient was randomized to receive NBI-1070770 for major depressive disorder in a phase 2 trial assessing efficacy, safety, and tolerability.

The study found the odds of a perinatal PTSD diagnosis were greater for people aged 15 – 26 years, more comorbidities, and a lower income of poverty.

The FDA approved iloperidone for acute treatment of bipolar I disorder on April 02, 2024, according to Vanda Pharmaceuticals.

Autism presents differently in males and females, which could explain why fewer females are diagnosed. Females are also often limited or excluded in autism research.

This March 2024 psychiatry month in review highlights positive phase 2b and phase 2a data for drugs targeting treatment-resistant depression, generalized anxiety disorder, and PTSD.

Abusing psychoactive substances, such as ADHD medication, cannabis, and nicotine, not only creates an addiction but can impact mental distress.

FDA issued a warning for the the Impella left-sided blood pumps as it had received many reports of heart-wall tears, increasing the risk of death, hypertension, and more.

A phase 2a open-label study found BL-003 for treatment-resistant depression was well-tolerated and any acute effects resolved on average in less than 2 hours.

A phase 2 trial found KP1077 provides clinically meaningful benefits for idiopathic hypersomnia.

A new study found sleep and emotional well-being are impacted days before women get their period.

In a new study, investigators evaluated if social contact influenced the age gap between biological age, estimated with artificial intelligence (AI), and chronological age.

In a recent UK study, more than half of stroke survivors developed depression within 18 years.

The hospitalization risk was reduced to up to 75% for patients with heart disease treated with both antidepressants and psychotherapy to manage anxiety or depression symptoms.

The SYMPHONY trial found reboxetine can significantly reduce cataplexy, excessive daytime sleepiness, cognitive impairment, depression, and anxiety for patients with narcolepsy.

With limited CBTi-trained psychologists, investigators assessed the effectiveness of a self-guided digital CBTi as another option, so people don’t have to turn to pills.

Bionomics announced the release of the full dataset analysis of the ATTUNE phase 2b trial; the data suggests BNC210 for PTSD could have an advantage over approved medications.

Vice Chair of the Performance Measurement Committee Rebecca A. Andrews spoke to HCPLive about the challenges with performance measures for treating major depressive disorder.

In an interview with HCPLive, Rebecca Andrews, MD, provided insight into the way the American College of Physicians voted on the performance measures for MDD.